Hewida H. Fadel, Mohamed Abd El-Rahman Ahmed, Kareem MahamoudGharbeya, Mohammed Ahmed Khamis Mohamed, Reda Almiry
Fadel H H, Ahmed M A E, MahamoudGharbeya K, Mohamed M A K, Almiry R. After Successful of Tocilizumab Plus Micronutrients in The Treatment of COVID19 Patients; Cosentyx May Be Recommended. Int j pharm phytopharm res 2020;10(4):161-8
By 23rd August 2020, 23,057,288 confirmed cases with SARS-CoV-2 that causes 800,906 deaths worldwide. The severe illness and high mortality are attributed to the dysregulation of hematopoiesis accompanied by cytokines storm. The severe illness and high mortality rate confirm the failure of the conventional strategy in the treatment of COVID19 patients. Also, lack of a specific vaccine or therapies target for SARS-CoV-2 infection, the drug repositioning in the treatment of COVID19 patients is the only opportunity to face this pandemic. Thus, we highlight the implication of a novel strategy of treatment based on the inhibition of IL-6, the major player in a cytokine storm, using Tocilizumab, in combination with micronutrients including Zinc, Selenium, vitamin C, and Glutathione. Application of Tocilizumab in infectious diseases is considered as a new treatment protocol since its usual uses are in autoimmune diseases. In the present study, we analyze the data for COVID19 patients who showed cytokine storm due to elevated level of IL-6 and suffered from severe illness, fever, ARDS, and transferred to ICU in Armed Forces Hospital. We found that Tocilizumab plus micronutrients improves the clinical outcomes in these critical cases of COVID19 patients. Statistical analyses of biochemical parameters including complete blood count to evaluate the efficacy of this combined therapy on counteracting the effect of SARS-CoV-2 on the differential of blood cell ratios, pro-inflammatory parameters (CRP, D-dimer, and ferritin), liver, cardiac, and kidney function were carried out. Finally, based on the success of Tocilizumab, an IL-6 inhibitor, in the treatment of COVID19 patients, we recommend using Cosentyx that is an inhibitor of IL-17, a partner of IL-6 in the inflammation process.